The most common ocular surface adverse effects are DED, conjunctivitis, and corneal damage, while blepharitis and meibomian gland dysfunction appear to be related to only a few of these new drugs, such as immune checkpoint inhibitors, BRAF inhibitors, aromatase inhibitors, and proteasome inhibitors. This evidence concerns the gene CYP19A1 and conjunctivitis.